Actinium Pharmaceuticals Inc (ATNM) Stock Price, Quote & News

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle c...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 677 3870

Website: www.actiniumpharma.com

Address:

100 Park Avenue, 23rd Floor, New York, United States

Pinto72 May. 14 at 5:38 AM

$ATNM bYe OwT🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣

0 · Reply

greencheese500 May. 14 at 3:50 AM

$ATNM Buyout !!!

0 · Reply

dm4 May. 14 at 1:50 AM

$ATNM

0 · Reply

Pickerbefore May. 13 at 10:47 PM

$ATNM when is Seth going to take some of the money he got out of the company and buy company shares? I think he knows himself well and the answer is probably never.

0 · Reply

Pickerbefore May. 13 at 10:45 PM

$ATNM 50% of regular volume. No faith in Seth except to screw it up. He is really good at that.

0 · Reply

Investfaithfully May. 13 at 9:05 PM

$ATNM

0 · Reply

mich1282 May. 13 at 6:32 PM

$ATNM sooo, I’ve been down on this pos for a long time. But today I did some deep Ai research and the changes in the 10k are quite bullish, especially since Seth can’t fluff shit anymore as there is a lawsuit on their hands. That all said, that lawsuit gets dismissed and we could fly to 2-3 quickly. And then hopefully actimab-a datts gives us a double from there.

3 · Reply

Pinto72 May. 13 at 4:27 PM

$ATNM EXTREME dilution is inevitable. $0.16 AS SOON🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣🤣

0 · Reply

timfris May. 13 at 2:15 PM

$ATNM so the company raised money based on Iomab and ACT A for 10 years, they barely mention them anymore, and now pump preclinical work after blowing 10’s of millions, the CEO is accused of fraud by former employees, and stock down 98%?

2 · Reply

gooddoggie May. 12 at 9:49 PM

$ATNM This is what’s so great about ATNM. We don’t have all these tiresome price swings.

1 · Reply

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

2026-04-22T11:29:41.000Z - 21 days ago

Actinium presents data from Actimab-A studies at AACR

2026-04-22T11:23:31.000Z - 21 days ago

Actinium presents preclinical results for ATNM-400 at AACR

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

Apr 6, 2026, 7:30 AM EDT - 5 weeks ago

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Feb 17, 2026, 8:00 AM EST - 3 months ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

2025-12-12T13:50:27.000Z - 5 months ago

Actinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400

Dec 12, 2025, 8:45 AM EST - 5 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

2025-12-01T13:50:36.000Z - 5 months ago

Actinium Pharmaceuticals announces preclinical data for ATNM-400

Dec 1, 2025, 8:45 AM EST - 5 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Nov 17, 2025, 8:30 AM EST - 6 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

2025-10-27T11:15:51.000Z - 7 months ago

Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity

AZN JNJ

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-24T12:35:37.000Z - 7 months ago

Actinium presents preclinical data for ATNM-400

Oct 24, 2025, 8:30 AM EDT - 7 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-10-13T16:25:11.000Z - 7 months ago

Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program

Oct 13, 2025, 12:10 PM EDT - 7 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 8:30 AM EDT - 7 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-07-31T12:42:35.000Z - 10 months ago

Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer

Jul 31, 2025, 8:30 AM EDT - 10 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

2025-06-23T17:33:54.000Z - 11 months ago

Actinium highlights expanded data set for ATNM-400 in prostate cancer

Jun 23, 2025, 11:30 AM EDT - 11 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 12, 2025, 11:00 AM EDT - 11 months ago

Actinium Pharmaceuticals Transcript: Life Sciences Investor Forum

2025-05-20T12:31:41.000Z - 1 year ago

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

2025-05-06T12:50:27.000Z - 1 year ago

Actinium enrolls first patient on the trial studying Iomab-ACT

May 6, 2025, 8:45 AM EDT - 1 year ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Apr 30, 2025, 7:25 AM EDT - 1 year ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

2025-04-28T12:47:44.000Z - 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows efficacy in prostate cancer study

NVS

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

2025-04-28T12:13:37.000Z - 1 year ago

Actinium’s Actimab-A shows antileukemic activity in AML models

SNDX

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 24, 2025, 5:00 AM EDT - 1 year ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 10, 2025, 9:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Transcript: 15th Annual LD Micro Invitational 2025

2025-03-25T19:20:49.000Z - 1 year ago

Actinium Pharmaceuticals enters supply pact with Eckert & Ziegler

2025-03-20T12:11:16.000Z - 1 year ago

Actinium Pharma enters research collaboration with Memorial Sloan Kettering

2025-03-18T12:11:32.000Z - 1 year ago

Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination

BMY MRK

2025-03-17T12:59:13.000Z - 1 year ago

Actinium Pharmaceuticals reports Actimab-A + CLAG-M trial results

2025-03-11T12:42:03.000Z - 1 year ago

Actinium Pharmaceuticals initiates Actimab-A Triplet combination frontline trial

Pinto72 May. 14 at 5:38 AM

$ATNM bYe OwT🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣

0 · Reply

greencheese500 May. 14 at 3:50 AM

$ATNM Buyout !!!

0 · Reply

dm4 May. 14 at 1:50 AM

$ATNM

0 · Reply

Pickerbefore May. 13 at 10:47 PM

$ATNM when is Seth going to take some of the money he got out of the company and buy company shares? I think he knows himself well and the answer is probably never.

0 · Reply

Pickerbefore May. 13 at 10:45 PM

$ATNM 50% of regular volume. No faith in Seth except to screw it up. He is really good at that.

0 · Reply

Investfaithfully May. 13 at 9:05 PM

$ATNM

0 · Reply

mich1282 May. 13 at 6:32 PM

3 · Reply

Pinto72 May. 13 at 4:27 PM

$ATNM EXTREME dilution is inevitable. $0.16 AS SOON🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣🤣

0 · Reply

timfris May. 13 at 2:15 PM

2 · Reply

gooddoggie May. 12 at 9:49 PM

$ATNM This is what’s so great about ATNM. We don’t have all these tiresome price swings.

1 · Reply

Pinto72 May. 12 at 9:35 PM

$ATNM oPsHuNz EkSpArAsHuN @Biotrad3r 🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣

0 · Reply

Investfaithfully May. 12 at 1:54 PM

$ATNM let’s go!

0 · Reply

Investfaithfully May. 12 at 3:41 AM

$ATNM buuuuulllliiiiisssssshhhhhhhhhhhhhhhh

0 · Reply

Pinto72 May. 11 at 10:09 PM

$ATNM Strange that DONNA, likes her own comments after being radio silent for months. Now, @gbtrade has gone silent🤣🤣🤣🤣 She also liked her own comments until she was called out on her deceptive actions. bEyEiNg WiTh BoTh HaNdZ🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!!🤣🤣🤣🤣🤣🤣

0 · Reply

Pinto72 May. 11 at 8:44 PM

$ATNM Accelerated REVERSE value AS SOON!!!🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣

0 · Reply

Investfaithfully May. 11 at 8:00 PM

$ATNM 1 minute to get in!!!!!!

0 · Reply

Investfaithfully May. 11 at 7:57 PM

$ATNM what ever happened to RIGHT TO TRY FOR Patients ?????????

0 · Reply

Investfaithfully May. 11 at 7:56 PM

$ATNM potential is absolutely astounding here……MERCK please address the company….a win win for you …the patients and investors…..

0 · Reply

Pinto72 May. 11 at 7:43 PM

$ATNM Thank you, @johnny4skin for your STELLAR DD🚀🚀🚀🚀🚀 What are your thoughts on the upcoming EXTREME dilution? eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣

0 · Reply

johnny4cures May. 11 at 6:35 PM

$ATNM zoom in

0 · Reply

johnny4cures May. 11 at 6:32 PM

$ATNM raw data on the mentioned target

0 · Reply

johnny4cures May. 11 at 6:23 PM

$ATNM and finally for clarity

0 · Reply

Market Cap	40.79M
Revenue (ttm)	90,000.00
Net Income (ttm)	-33.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37,655.55%
Debt to Equity Ratio	0.00

Volume	76,700
Avg Vol	190,516
Day's Range	N/A - N/A
Shares Out	31.38M
Stochastic %K	67%
Beta	-0.11
Analysts	Strong Sell
Price Target	$5.00